{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,7]],"date-time":"2026-06-07T12:43:52Z","timestamp":1780836232867,"version":"3.54.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,8,22]],"date-time":"2024-08-22T00:00:00Z","timestamp":1724284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,8,22]],"date-time":"2024-08-22T00:00:00Z","timestamp":1724284800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Helmholtz Association","award":["HVF0079"],"award-info":[{"award-number":["HVF0079"]}]},{"name":"Helmholz Innovation lab","award":["DB001822"],"award-info":[{"award-number":["DB001822"]}]},{"DOI":"10.13039\/100000864","name":"The Michael J. Fox Foundation for Parkinson\u2019s Research","doi-asserted-by":"crossref","award":["14977"],"award-info":[{"award-number":["14977"]}],"id":[{"id":"10.13039\/100000864","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000864","name":"The Michael J. Fox Foundation for Parkinson\u2019s Research","doi-asserted-by":"crossref","award":["009889"],"award-info":[{"award-number":["009889"]}],"id":[{"id":"10.13039\/100000864","id-type":"DOI","asserted-by":"crossref"}]},{"name":"ALS Association and from the Packard Center","award":["19-SI-476"],"award-info":[{"award-number":["19-SI-476"]}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"crossref","award":["INST 208\/616-1 FUGG"],"award-info":[{"award-number":["INST 208\/616-1 FUGG"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"crossref","award":["INST 208\/794-1 FUGG"],"award-info":[{"award-number":["INST 208\/794-1 FUGG"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Forschungszentrum J\u00fclich GmbH"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Islet amyloid polypeptide (IAPP) is co-secreted with insulin from pancreatic \u00df-cells. Its oligomerisation is regarded as disease driving force in type 2 diabetes (T2D) pathology. Up to now, IAPP oligomers have been detected in affected tissues. IAPP oligomer concentrations in blood have not been analysed so far. Using the IAPP single-oligomer-sensitive and monomer-insensitive surface-based fluorescence intensity distribution analysis (sFIDA) technology, levels of IAPP oligomers in blood plasma from healthy controls and people with T2D in different disease stages where determined. Subsequently, the level of IAPP oligomerisation was introduced as the ratio between the IAPP oligomers determined with sFIDA and the total IAPP concentration determined with ELISA. Highest oligomerisation levels were detected in plasma of people with T2D without late complication and without insulin therapy. Their levels stand out significantly from the control group. Healthy controls presented with the lowest oligomerisation levels in plasma. In people with T2D without complications, IAPP oligomerisation levels correlated with disease duration. The results clearly demonstrate that IAPP oligomerisation in insulin-na\u00efve patients correlates with duration of T2D. Although a correlation per se does not identify, which is cause and what is consequence, this result supports the hypothesis that IAPP aggregation is the driving factor of T2D development and progression. The alternative and conventional hypothesis explains development of T2D with increasing insulin resistance causing exhaustion of pancreatic \u00df-cells due to over-secretion of insulin, and thus IAPP, too, resulting in subsequent IAPP aggregation and fibril deposition in the pancreas. Further experiments and comparative analyses with primary tissues are warranted.<\/jats:p>","DOI":"10.1038\/s41598-024-70255-3","type":"journal-article","created":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T15:32:45Z","timestamp":1724427165000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["IAPP - oligomerisation levels in plasma of people with type 2 diabetes"],"prefix":"10.1038","volume":"14","author":[{"given":"Fabian","family":"Rehn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Kraemer-Schulien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tuyen","family":"Bujnicki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Bannach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diethelm","family":"Tschoepe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernd","family":"Stratmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dieter","family":"Willbold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,22]]},"reference":[{"key":"70255_CR1","doi-asserted-by":"publisher","first-page":"S29","DOI":"10.1038\/sj.ijo.0801273","volume":"24","author":"K Polonsky","year":"2000","unstructured":"Polonsky, K. Dynamics of insulin secretion in obesity and diabetes. Int. J. Obes. 24, S29\u2013S31 (2000).","journal-title":"Int. J. Obes."},{"key":"70255_CR2","doi-asserted-by":"publisher","first-page":"102","DOI":"10.2337\/diabetes.52.1.102","volume":"52","author":"AE Butler","year":"2003","unstructured":"Butler, A. E. et al. \u03b2-cell deficit and increased \u03b2-cell apoptosis in humans with type 2 diabetes. Diabetes 52, 102\u2013110 (2003).","journal-title":"Diabetes"},{"key":"70255_CR3","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1080\/17446651.2023.2279533","volume":"19","author":"J Meir","year":"2024","unstructured":"Meir, J. et al. The vascular complications of diabetes: A review of their management, pathogenesis, and prevention. Expert Rev. Endocrinol. Metab. 19, 11\u201320 (2024).","journal-title":"Expert Rev. Endocrinol. Metab."},{"key":"70255_CR4","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003054.pub3","author":"LJ Orozco","year":"2008","unstructured":"Orozco, L. J. et al. Exercise or exercise and diet for preventing type 2 diabetes mellitus. Cochrane Database Syst. Rev. https:\/\/doi.org\/10.1002\/14651858.CD003054.pub3 (2008).","journal-title":"Cochrane Database Syst. Rev."},{"key":"70255_CR5","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1038\/nature05616","volume":"445","author":"R Sladek","year":"2007","unstructured":"Sladek, R. et al. A genome-wide association study identifies novel risk loci for type 2 diabetes. Nature 445, 881\u2013885 (2007).","journal-title":"Nature"},{"key":"70255_CR6","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.1016\/S0140-6736(17)30058-2","volume":"389","author":"S Chatterjee","year":"2017","unstructured":"Chatterjee, S., Khunti, K. & Davies, M. J. Type 2 diabetes. Lancet 389, 2239\u20132251 (2017).","journal-title":"Lancet"},{"key":"70255_CR7","doi-asserted-by":"publisher","first-page":"107","DOI":"10.2991\/jegh.k.191028.001","volume":"10","author":"M Abdul Basith Khan","year":"2020","unstructured":"Abdul Basith Khan, M. et al. Epidemiology of type 2 diabetes\u2014Global burden of disease and forecasted trends. J. Epidemiol. Glob. Health 10, 107\u2013111 (2020).","journal-title":"J. Epidemiol. Glob. Health"},{"key":"70255_CR8","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1210\/er.2007-0037","volume":"29","author":"L Haataja","year":"2008","unstructured":"Haataja, L., Gurlo, T., Huang, C. J. & Butler, P. C. Islet amyloid in type 2 diabetes, and the toxic oligomer hypothesis. Endocr. Rev. 29, 303\u2013316 (2008).","journal-title":"Endocr. Rev."},{"key":"70255_CR9","doi-asserted-by":"publisher","first-page":"2449","DOI":"10.1016\/S0140-6736(18)31320-5","volume":"391","author":"LA DiMeglio","year":"2018","unstructured":"DiMeglio, L. A., Evans-Molina, C. & Oram, R. A. Type 1 diabetes. Lancet 391, 2449\u20132462 (2018).","journal-title":"Lancet"},{"key":"70255_CR10","doi-asserted-by":"publisher","first-page":"634","DOI":"10.2337\/diab.39.5.634","volume":"39","author":"SE Kahn","year":"1990","unstructured":"Kahn, S. E. et al. Evidence of cosecretion of islet amyloid polypeptide and insulin by \u03b2-cells. Diabetes 39, 634\u2013638 (1990).","journal-title":"Diabetes"},{"key":"70255_CR11","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1007\/BF00410276","volume":"38","author":"H Mulder","year":"1995","unstructured":"Mulder, H., Ahren, B., Stridsberg, M. & Sundler, F. Non-parallelism of islet amyloid polypeptide (amylin) and insulin gene expression in rat islets following dexamethasone treatment. Diabetologia 38, 395\u2013402 (1995).","journal-title":"Diabetologia"},{"key":"70255_CR12","doi-asserted-by":"publisher","first-page":"5036","DOI":"10.1073\/pnas.87.13.5036","volume":"87","author":"P Westermark","year":"1990","unstructured":"Westermark, P., Engstr\u00f6m, U., Johnson, K. H., Westermark, G. T. & Betsholtz, C. Islet amyloid polypeptide: Pinpointing amino acid residues linked to amyloid fibril formation. Proc. Natl. Acad. Sci. 87, 5036\u20135040 (1990).","journal-title":"Proc. Natl. Acad. Sci."},{"key":"70255_CR13","doi-asserted-by":"publisher","first-page":"241","DOI":"10.2337\/diabetes.48.2.241","volume":"48","author":"SE Kahn","year":"1999","unstructured":"Kahn, S. E., Andrikopoulos, S. & Verchere, C. B. Islet amyloid: A long-recognized but underappreciated pathological feature of type 2 diabetes. Diabetes 48, 241\u2013253 (1999).","journal-title":"Diabetes"},{"key":"70255_CR14","doi-asserted-by":"publisher","first-page":"491","DOI":"10.2337\/diabetes.48.3.491","volume":"48","author":"J Janson","year":"1999","unstructured":"Janson, J., Ashley, R. H., Harrison, D., McIntyre, S. & Butler, P. C. The mechanism of islet amyloid polypeptide toxicity is membrane disruption by intermediate-sized toxic amyloid particles. Diabetes 48, 491\u2013498 (1999).","journal-title":"Diabetes"},{"key":"70255_CR15","doi-asserted-by":"publisher","first-page":"861","DOI":"10.2353\/ajpath.2010.090532","volume":"176","author":"T Gurlo","year":"2010","unstructured":"Gurlo, T. et al. Evidence for proteotoxicity in \u03b2 cells in type 2 diabetes: Toxic islet amyloid polypeptide oligomers form intracellularly in the secretory pathway. Am. J. Pathol. 176, 861\u2013869 (2010).","journal-title":"Am. J. Pathol."},{"key":"70255_CR16","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.2337\/db06-1579","volume":"56","author":"C-Y Lin","year":"2007","unstructured":"Lin, C.-Y. et al. Toxic human islet amyloid polypeptide (h-IAPP) oligomers are intracellular, and vaccination to induce anti-toxic oligomer antibodies does not prevent h-IAPP\u2013induced \u03b2-cell apoptosis in h-IAPP transgenic mice. Diabetes 56, 1324\u20131332 (2007).","journal-title":"Diabetes"},{"key":"70255_CR17","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s13340-018-0347-1","volume":"9","author":"A Kanatsuka","year":"2018","unstructured":"Kanatsuka, A., Kou, S. & Makino, H. IAPP\/amylin and \u03b2-cell failure: Implication of the risk factors of type 2 diabetes. Diabetol. Int. 9, 143\u2013157 (2018).","journal-title":"Diabetol. Int."},{"key":"70255_CR18","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1038\/ni.1935","volume":"11","author":"SL Masters","year":"2010","unstructured":"Masters, S. L. et al. Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1\u03b2 in type 2 diabetes. Nat. Immunol. 11, 897\u2013904 (2010).","journal-title":"Nat. Immunol."},{"key":"70255_CR19","doi-asserted-by":"publisher","first-page":"8285","DOI":"10.1021\/acs.chemrev.1c00196","volume":"121","author":"D Willbold","year":"2021","unstructured":"Willbold, D., Strodel, B., Schr\u00f6der, G. F., Hoyer, W. & Heise, H. Amyloid-type protein aggregation and prion-like properties of amyloids. Chem. Rev. 121, 8285\u20138307 (2021).","journal-title":"Chem. Rev."},{"key":"70255_CR20","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1038\/mp.2016.230","volume":"22","author":"I Moreno-Gonzalez","year":"2017","unstructured":"Moreno-Gonzalez, I. et al. Molecular interaction between type 2 diabetes and Alzheimer\u2019s disease through cross-seeding of protein misfolding. Mol. Psychiatry 22, 1327\u20131334 (2017).","journal-title":"Mol. Psychiatry"},{"key":"70255_CR21","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1038\/s41594-020-0442-4","volume":"27","author":"C R\u00f6der","year":"2020","unstructured":"R\u00f6der, C. et al. Cryo-EM structure of islet amyloid polypeptide fibrils reveals similarities with amyloid-\u03b2 fibrils. Nat. Struct. Mol. Biol. 27, 660\u2013667 (2020).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"70255_CR22","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1126\/science.aao2825","volume":"358","author":"L Gremer","year":"2017","unstructured":"Gremer, L. et al. Fibril structure of amyloid-\u03b2 (1\u201342) by cryo\u2013electron microscopy. Science 358, 116\u2013119 (2017).","journal-title":"Science"},{"key":"70255_CR23","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1021\/acschemneuro.5b00192","volume":"6","author":"R Hu","year":"2015","unstructured":"Hu, R., Zhang, M., Chen, H., Jiang, B. & Zheng, J. Cross-seeding interaction between \u03b2-amyloid and human islet amyloid polypeptide. ACS Chem. Neurosci. 6, 1759\u20131768 (2015).","journal-title":"ACS Chem. Neurosci."},{"key":"70255_CR24","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1038\/s41531-022-00330-x","volume":"8","author":"L Bl\u00f6meke","year":"2022","unstructured":"Bl\u00f6meke, L. et al. Quantitative detection of \u03b1-Synuclein and Tau oligomers and other aggregates by digital single particle counting. NPJ Parkinson\u2019s Dis. 8, 68 (2022).","journal-title":"NPJ Parkinson's Dis."},{"key":"70255_CR25","volume":"16","author":"L Bl\u00f6meke","year":"2024","unstructured":"Bl\u00f6meke, L. et al. A\u03b2 oligomers peak in early stages of Alzheimer\u2019s disease preceding tau pathology. Alzheimer\u2019s Dement. Diagn. Assess. Dis. .Monit. 16, e12589 (2024).","journal-title":"Alzheimer's Dement. Diagn. Assess. Dis. .Monit."},{"key":"70255_CR26","doi-asserted-by":"publisher","first-page":"100630","DOI":"10.1016\/j.xcrm.2022.100630","volume":"3","author":"B Kass","year":"2022","unstructured":"Kass, B. et al. A\u03b2 oligomer concentration in mouse and human brain and its drug-induced reduction ex vivo. Cell Rep. Med. 3, 100630 (2022).","journal-title":"Cell Rep. Med."},{"key":"70255_CR27","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1515\/hsz-2016-0153","volume":"398","author":"K Kravchenko","year":"2017","unstructured":"Kravchenko, K. et al. Analysis of anticoagulants for blood-based quantitation of amyloid \u03b2 oligomers in the sFIDA assay. Biol. Chem. 398, 465\u2013475 (2017).","journal-title":"Biol. Chem."},{"key":"70255_CR28","doi-asserted-by":"publisher","first-page":"5426","DOI":"10.1039\/C8CC03097A","volume":"54","author":"DCR Camargo","year":"2018","unstructured":"Camargo, D. C. R. et al. hIAPP forms toxic oligomers in plasma. Chem. Commun. 54, 5426\u20135429 (2018).","journal-title":"Chem. Commun."},{"key":"70255_CR29","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.jmb.2003.10.045","volume":"335","author":"JL Larson","year":"2004","unstructured":"Larson, J. L. & Miranker, A. D. The mechanism of insulin action on islet amyloid polypeptide fiber formation. J. Mol. Biol. 335, 221\u2013231 (2004).","journal-title":"J. Mol. Biol."},{"key":"70255_CR30","doi-asserted-by":"publisher","first-page":"4244","DOI":"10.1039\/C8SC00481A","volume":"9","author":"M Baram","year":"2018","unstructured":"Baram, M., Gilead, S., Gazit, E. & Miller, Y. Mechanistic perspective and functional activity of insulin in amylin aggregation. Chem. Sci. 9, 4244\u20134252 (2018).","journal-title":"Chem. Sci."},{"key":"70255_CR31","doi-asserted-by":"publisher","first-page":"6626","DOI":"10.1002\/ange.200602034","volume":"118","author":"S Gilead","year":"2006","unstructured":"Gilead, S., Wolfenson, H. & Gazit, E. Molecular mapping of the recognition interface between the islet amyloid polypeptide and insulin. Angew. Chem. 118, 6626\u20136630 (2006).","journal-title":"Angew. Chem."},{"key":"70255_CR32","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1002\/ana.23956","volume":"74","author":"K Jackson","year":"2013","unstructured":"Jackson, K. et al. Amylin deposition in the brain: A second amyloid in Alzheimer disease?. Ann. Neurol. 74, 517\u2013526 (2013).","journal-title":"Ann. Neurol."},{"key":"70255_CR33","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1001\/jama.2021.4001","volume":"325","author":"CB Amidei","year":"2021","unstructured":"Amidei, C. B. et al. Association between age at diabetes onset and subsequent risk of dementia. JAMA 325, 1640\u20131649 (2021).","journal-title":"JAMA"},{"key":"70255_CR34","doi-asserted-by":"publisher","first-page":"778","DOI":"10.3390\/biomedicines10040778","volume":"10","author":"A Athanasaki","year":"2022","unstructured":"Athanasaki, A. et al. Type 2 diabetes mellitus as a risk factor for Alzheimer\u2019s disease: Review and meta-analysis. Biomedicines 10, 778 (2022).","journal-title":"Biomedicines"},{"key":"70255_CR35","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.ab.2010.07.015","volume":"406","author":"L Liu","year":"2010","unstructured":"Liu, L. et al. Differences in metabolite profile between blood plasma and serum. Anal. Biochem. 406, 105\u2013112 (2010).","journal-title":"Anal. Biochem."},{"key":"70255_CR36","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1002\/ana.24992","volume":"82","author":"H Ly","year":"2017","unstructured":"Ly, H. et al. Brain microvascular injury and white matter disease provoked by diabetes-associated hyperamylinemia. Ann. Neurol. 82, 208\u2013222 (2017).","journal-title":"Ann. Neurol."},{"key":"70255_CR37","doi-asserted-by":"publisher","first-page":"104682","DOI":"10.1016\/j.jbc.2023.104682","volume":"299","author":"D Kotiya","year":"2023","unstructured":"Kotiya, D. et al. Rapid, scalable assay of amylin-\u03b2 amyloid co-aggregation in brain tissue and blood. J. Biol. Chem. 299, 104682 (2023).","journal-title":"J. Biol. Chem."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-70255-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-70255-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-70255-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T15:36:10Z","timestamp":1724427370000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-70255-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,22]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["70255"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-70255-3","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,22]]},"assertion":[{"value":"13 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"BS has none to declare. DW and OB are co-founder and co-owner of attyloid GmbH, which is commercializing the sFIDA technology. This did not influence any data interpretation. All the remaining authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"19556"}}